Key Takeaways:
- TrumpRx launched February 6, 2026, offering direct-to-consumer GLP-1 pricing at $150-350/month
- Monthly costs dropped from over $1,300 to as low as $149 for oral semaglutide and $346 for Zepbound
- Medicare now covers GLP-1s for obesity for the first time with $50 monthly copays
Government Platform Delivers Promised Price Cuts
President Trump officially launched the TrumpRx website and savings program on February 6, delivering on promises to slash the cost of America's most expensive medications. The platform allows consumers who don't have or don't want to use health insurance to purchase many high cost prescription drugs directly from pharmaceutical companies.
The launch represents the culmination of Most Favored Nation executive order agreements with Eli Lilly and Novo Nordisk to address US drug pricing disparities. By leveraging "Most Favored Nation" (MFN) pricing deals with pharmaceutical giants Eli Lilly and Novo Nordisk, the administration has successfully slashed the cost of life-changing GLP-1 medications—including Wegovy, Ozempic, and Zepbound.
At launch, people purchasing medications directly through TrumpRx will see price reductions on 40 of the most popular, high-priced branded medications nationwide, with GLP-1 drugs representing the biggest savings opportunity for Americans.
Dramatic Price Reductions Across All GLP-1 Options
The price cuts are substantial across all major GLP-1 medications. According to the White House press release, the monthly cost of Ozempic and injectable Wegovy will fall from $1,028 and $1,349, respectively, to an average price of $399 and as low as $150, depending on the dosage strength.
The monthly price of the Wegovy pill will reduce from $1,349 to as low as $149, depending on dosage. For those considering semaglutide injection, these savings could make treatment accessible for the first time.
Zepbound will fall from $1,088 to an average price of $346, with a low of $299, depending on dosage strength. For new oral GLP-1 options, the lowest dose of orforglipron would start at $149 if approved. The pricing structure creates clear pathways for people to start treatment at lower doses while maintaining affordability as they progress to higher, more effective doses.
Medicare Expansion: First-Ever Obesity Coverage
Perhaps the most significant change is Medicare's expansion into obesity treatment. For the first time, coverage for weight-loss medications will be available to Medicare beneficiaries with obesity who don't also have related health conditions such as diabetes or cardiovascular issues.
Under the CMMI demo, as Medicare reduces the prices it pays to Eli Lilly and Novo Nordisk for GLP-1s to treat diabetes, cardiovascular disease, and possible future indications, it can use the savings to pay for the expansion of coverage for GLP-1 drugs solely for weight loss. Medicare beneficiaries will have a $50 monthly copay for the newly covered obesity indications.
By negotiating the government's purchase price down to $245 per month, the administration has made it financially sustainable for Medicare to provide these drugs with a minimal $50 patient copay. This represents a fundamental shift in how Medicare approaches obesity as a medical condition requiring treatment.
Impact on Private Insurance and Employer Plans
The TrumpRx pricing model is already influencing private insurance coverage decisions. In 2025, nearly half of all large employers cover GLP-1 medications approved for weight loss. Assuming Medicare will now cover GLP-1s solely for weight loss, the pressure for employers to provide this coverage may grow.
But if the lower DTC prices negotiated by the Trump administration "trickle down" to employer-sponsored health plans, adding or maintaining this coverage may become more feasible. Insurance companies and pharmacy benefit managers are being forced to compete with these government-negotiated prices.
However, there are important limitations. As of now, insurance policies are unlikely to count cash-pay transactions outside the benefit towards plan deductible/OOP balances. This means people using TrumpRx may miss out on reaching their insurance deductibles, potentially costing more in the long run for other medical expenses.
Platform Access and Real-World Experience
TrumpRx is a cash-pay channel. It may complement, but currently doesn't replace, insurance plan design and negotiated PBM pricing. The platform operates by connecting consumers directly to manufacturer programs, often redirecting to existing direct-pay options like LillyDirect and NovoCare.
You still need a valid prescription from a licensed healthcare provider. The portal will often redirect you to LillyDirect or NovoCare. Because these sites are now integrated with TrumpRX, the MFN discounts are automatically applied.
One significant limitation: No clinical support is built in. TrumpRx connects you to the medication, not to a care team. You still need a prescriber, labs, dosing guidance, and ongoing monitoring from somewhere else. This makes it essential to work with experienced providers who understand GLP-1 treatment protocols.
What This Means for You
TrumpRx represents the most significant shift in GLP-1 accessibility since these medications first launched. If you're uninsured or underinsured, these price cuts could finally make treatment affordable. For uninsured or underinsured patients, these are meaningful savings.
If you have insurance, the calculation is more complex. For patients with decent pharmacy coverage, the math is less clear. You'll need to compare your current insurance copays against TrumpRx pricing, factoring in whether cash payments count toward your deductible.
For Medicare beneficiaries, this could be life-changing. The new $50 monthly copay for obesity treatment creates an entirely new pathway to access these medications through your existing Medicare coverage.
Before making any changes to your treatment plan, compare your current options with what's available through TrumpRx. Consider working with providers who understand both insurance-based and cash-pay options to help you navigate these new pricing structures effectively. Finding the right clinical support remains crucial, as you'll still need comprehensive care beyond medication access alone.
Sources
- TrumpRx Launch Brings Savings—and Uncertainty - AJMC - Analysis of TrumpRx platform launch and pricing
- TrumpRx Launches to Help Lower Prices of GLP-1s - Healthline - Details on platform launch and medication savings
- TrumpRx and MFN Pricing: What Plan Sponsors Should Know - Truveris - Analysis of platform impact on insurance benefits
- Trump announces lower GLP-1 prices - Mercer - Impact on employer health plans
- LillyDirect, TrumpRx & NovoCare: Real GLP-1 Prices Explained - Affinity Whole Health - Comparison of direct-pay platforms